Attending major scientific congresses is one of the highest-stakes activities for pharma teams. Done well, they unlock deeper scientific insights, strengthen key relationships, and create a competitive advantage. Done poorly, they become a missed opportunity — and a major budget sink. ... Read this blog
The pharmaceutical landscape has never been more demanding. Medical Affairs, Commercial, and Field are expected to do more with less while delivering greater scientific value. All the while, conforming to airtight compliance and keeping pace with rapidly evolving expectations. ... Read this blog
Medical Affairs strategy has always been relationship-driven. But in the wake of digital transformation in healthcare communication, face-to-face touchpoints are now just one part of the bigger picture. KOLs (Key Opinion Leaders) and DOLs (Digital Opinion Leaders) in healthcare now expect fast, personalized, and informed interactions that go beyond traditional ways of engagement. ... Read this blog
In oncology, the right voices don’t just inform, they inspire action. For years, that voice has belonged to the oncology key opinion leaders. These individuals are senior oncologists at the podium, principal investigators (PIs) of landmark trials, or authors of impactful studies. Their influence shapes treatment paradigms, drives clinical adoption, and builds trust in emerging science. ... Read this blog
Life sciences industry–HCP relationships today are undergoing a major transformation. Medical Affairs, MSLs, and other scientific teams need to wade through a sea of HCPs and complex regulatory framework to engage the right experts. ... Read this blog
Key Opinion Leaders (KOLs) are more than just respected voices in their specialties. They’re strategic partners who influence everything from clinical trial adoption to treatment guidelines and payer decisions.
... Read this blog
Not every hospital visit is planned. Sometimes, it could be a sudden health scare or an accident that needs urgent attention. In those moments, acute care settings are where people turn to. These settings admit the patients and initiate treatment quickly so patients can get back to normalcy as safely and efficiently as possible.
... Read this blog
The U.S. pharmaceutical landscape is undergoing a major transformation. To navigate this shift, life sciences teams are increasingly leveraging tools, including KOL management software and Scientific Share of Voice (SSoV) metrics. Yes, medical affairs teams are moving beyond traditional outreach and marketing tactics, embracing a new era of data-driven engagement with Key Opinion Leaders (KOLs). ... Read this blog
In Medical Affairs, timing is everything. Engaging a key opinion leader (KOL) too late after their priorities have shifted can mean missed opportunities. Static expert lists may once have sufficed, but they no longer reflect the pace of today’s influence landscape.
... Read this blog
Engaging with the right Key Opinion Leaders (KOLs) is a core responsibility for Medical Affairs teams. ... Read this blog
Not every expert is a key opinion leader (KOL), and not every KOL is the right fit. In a market as saturated and specialized as U.S. healthcare, pharma teams need more than a name and a title. They need context. They need clarity. Above all, teams need to be sure their engagement efforts focus on the experts who truly influence medical decisions. ... Read this blog
Who truly shapes how treatments are adopted in the real world? Which experts hold sway over clinical peers, influence prescribing behavior, or spark scientific conversations online?
For U.S. medical affairs teams, these aren't abstract questions—they’re operational imperatives. Identifying the right key opinion leaders (KOLs) is central to product launches, scientific exchange, and market education. But the rules of engagement have changed. ... Read this blog
Recommended
